Cognitive Assessment in Patients with Primary Aldosteronism versus Patients with Mild Autonomous Cortisol Secretion.

Abstract

Data on cognition in patients with primary aldosteronism (PA) are scarce. Mild autonomous cortisol secretion (MACS), defined based on post-dexamethasone cortisol >1.8 mcg/dL, is diagnosed in up to 30% of patients with PA. 1) assess cognition in patients with PA versus referent subjects with hypertension, 2) determine differences in cognition between patients with PA and those with MACS. A prospective, cross-sectional study, 2019-2023. Cognition was assessed by National Institute of Health Toolbox Cognition Battery and reported as T-scores corrected for age, sex, race, and education. Only subjects with hypertension were included. Cognitive assessment was performed in 52 patients with PA (including 11 patients with both PA and MACS, median age of 51.0 years, 30 (57.7%) women), 47 patients with MACS (median age of 57.0 years, 31 (66.0%) women), and 52 referent subjects (median age of 66.1 years, 30 (57.7%) women). When compared to referents, and after adjusting for age, smoking, systolic blood pressure and alcohol use, patients with PA had lower total cognition (β=-5.7, P=0.023), notably fluid cognition (β=-6.8, P=0.017), including attention and executive function (β=-5.6, P=0.012) and cognitive flexibility and executive function (β=-8.2, P=0.006). When compared to patients with MACS, patients with PA had a higher processing speed (β=9.0, P=0.003). No differences in cognition were found between patients with PA with and without MACS. Patients with PA demonstrated lower cognition compared with referents and processing speed compared with MACS. Future studies should characterize the impact of MACS on the cognition of patients with PA.